KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 75.04M | 15.12M | 1.43M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.04M | 15.12M | 1.43M | -- | -- |
| Cost of Revenue | 57.11M | 57.46M | 62.92M | 73.78M | 83.14M |
| Gross Profit | 17.94M | -42.34M | -61.49M | -73.78M | -83.14M |
| SG&A Expenses | 190.74M | 160.69M | 138.97M | 111.89M | 95.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 247.85M | 218.15M | 201.89M | 185.67M | 179.09M |
| Operating Income | -172.81M | -203.03M | -200.46M | -185.67M | -179.09M |
| Income Before Tax | -170.82M | -202.61M | -194.37M | -176.87M | -168.44M |
| Income Tax Expenses | -3.64M | 7.71M | 5.55M | 3.39M | 4.25M |
| Earnings from Continuing Operations | -167.18 | -210.31 | -199.92 | -180.26 | -172.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -167.18M | -210.31M | -199.92M | -180.26M | -172.69M |
| EBIT | -172.81M | -203.03M | -200.46M | -185.67M | -179.09M |
| EBITDA | -171.42M | -202.00M | -199.50M | -184.73M | -178.20M |
| EPS Basic | -3.12 | -3.95 | -3.87 | -3.62 | -3.66 |
| Normalized Basic EPS | -2.01 | -2.40 | -2.37 | -2.24 | -2.25 |
| EPS Diluted | -3.12 | -3.95 | -3.87 | -3.62 | -3.66 |
| Normalized Diluted EPS | -2.01 | -2.40 | -2.37 | -2.24 | -2.25 |
| Average Basic Shares Outstanding | 215.61M | 213.06M | 205.77M | 198.51M | 189.05M |
| Average Diluted Shares Outstanding | 215.61M | 213.06M | 205.77M | 198.51M | 189.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |